Conferences Archives - PsychoGenics

Characterization of the Rat Monoiodoacetate Model of Osteoarthritis: Evoked and Non-evoked Pain Response Assessments

by Irene Morgenstern | Mar 11, 2022

Efforts to accelerate development of non-opioid, non-addictive pain therapeutics within the NIH HEAL Initiative Preclinical Screening Platform for Pain and validation examples

by Irene Morgenstern | Mar 11, 2022

The NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP) efforts to validate rodent models of pain and migraine

by Irene Morgenstern | Mar 11, 2022

Microglia and the NLRP3 inflammasome pathway contribute to Tau-mediated pathology in vivo

by Irene Morgenstern | Mar 11, 2022

Christopher Dumayne1, Davide Basco1, Alessio Mylonas1, Yvan Varisco1, Daniel Havas2, Patrick Rodriguez1, Francesca Capotosti1, Nicolas Fournier1, Kasia Piorkowska1, Emanuele Gabellieri1, Mickaël Audrain1, Sonia Poli1, Andrea Pfeifer1, Marie Kosco-Vilbois1 and Tamara...

Translational Utility of Mismatch Negativity: Implementing MMN in rats for Drug Discovery

by admin | Jun 2, 2019

S.C. LEISER1, D. BREGNA1, E. LEAHY1 1Translational EEG, PsychoGenics, Inc., Paramus, NJ, USA Background Mismatch negativity (MMN) is a validated, objective measure of central auditory processing and has become a key clinical biomarker in schizophrenia. MMN is an...

Characterization of the Rat Monoiodoacetate Model of Osteoarthritis: Evoked and Non-evoked Pain Response Assessments

Efforts to accelerate development of non-opioid, non-addictive pain therapeutics within the NIH HEAL Initiative Preclinical Screening Platform for Pain and validation examples

The NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP) efforts to validate rodent models of pain and migraine

Microglia and the NLRP3 inflammasome pathway contribute to Tau-mediated pathology in vivo

Translational Utility of Mismatch Negativity: Implementing MMN in rats for Drug Discovery

Recent Comments

CONTACT